CN111448212A - 抗trem2抗体及其使用方法 - Google Patents

抗trem2抗体及其使用方法 Download PDF

Info

Publication number
CN111448212A
CN111448212A CN201880069782.0A CN201880069782A CN111448212A CN 111448212 A CN111448212 A CN 111448212A CN 201880069782 A CN201880069782 A CN 201880069782A CN 111448212 A CN111448212 A CN 111448212A
Authority
CN
China
Prior art keywords
amino acid
seq
sequence
acid sequence
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880069782.0A
Other languages
English (en)
Chinese (zh)
Inventor
陈航
吉尔伯特·迪保罗
郝睿
约瑟夫·W·雷洛克
艾丽西娅·A·纽金特
里希·拉科赫特
施菊
林坎·舒克拉
贝蒂娜·范伦格里奇
章莹
内森·莫尔克
安基塔·斯利瓦斯塔瓦
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Denali Therapeutics Inc
Original Assignee
Denali Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Denali Therapeutics Inc filed Critical Denali Therapeutics Inc
Publication of CN111448212A publication Critical patent/CN111448212A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/10—Protein-tyrosine kinases (2.7.10)
    • C12Y207/10002—Non-specific protein-tyrosine kinase (2.7.10.2), i.e. spleen tyrosine kinase

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN201880069782.0A 2017-09-14 2018-09-14 抗trem2抗体及其使用方法 Pending CN111448212A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201762558803P 2017-09-14 2017-09-14
US62/558,803 2017-09-14
US201762583379P 2017-11-08 2017-11-08
US62/583,379 2017-11-08
US201862621380P 2018-01-24 2018-01-24
US62/621,380 2018-01-24
PCT/US2018/051166 WO2019055841A1 (en) 2017-09-14 2018-09-14 ANTI-TREM2 ANTIBODIES AND METHODS OF USE

Publications (1)

Publication Number Publication Date
CN111448212A true CN111448212A (zh) 2020-07-24

Family

ID=63714159

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880069782.0A Pending CN111448212A (zh) 2017-09-14 2018-09-14 抗trem2抗体及其使用方法

Country Status (6)

Country Link
US (1) US20200277373A1 (cg-RX-API-DMAC7.html)
EP (1) EP3681909A1 (cg-RX-API-DMAC7.html)
JP (3) JP7403441B2 (cg-RX-API-DMAC7.html)
CN (1) CN111448212A (cg-RX-API-DMAC7.html)
CA (1) CA3075285A1 (cg-RX-API-DMAC7.html)
WO (1) WO2019055841A1 (cg-RX-API-DMAC7.html)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112526143A (zh) * 2020-12-03 2021-03-19 中山大学附属第五医院 髓系细胞触发受体2作为新型冠状病毒肺炎诊断或治疗靶点的应用
CN114667295A (zh) * 2019-11-22 2022-06-24 伊莱利利公司 Trem2抗体及其用途
CN117534569A (zh) * 2023-11-23 2024-02-09 复旦大学附属华山医院 S-9-pahsa在制备阿尔兹海默病及认知障碍疾病治疗药物中的用途
CN117964768A (zh) * 2024-04-02 2024-05-03 上海宏成药业有限公司 抗trem2抗体及其用途
WO2024250809A1 (zh) * 2023-06-08 2024-12-12 成都优洛生物科技有限公司 抗trem2全人源抗体或其抗原结合片段及其应用

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201790342A1 (ru) 2014-08-08 2017-07-31 ЭЛЕКТОР ЭлЭлСи Антитела к trem2 и способы их применения
KR20240056629A (ko) 2014-09-28 2024-04-30 더 리전트 오브 더 유니버시티 오브 캘리포니아 자극성 및 비자극성 골수성 세포의 조절
RS63818B1 (sr) 2017-02-17 2023-01-31 Denali Therapeutics Inc Konstruisani polipeptidi za vezivanje za receptor transferina
JOP20190248A1 (ar) 2017-04-21 2019-10-20 Amgen Inc بروتينات ربط مولد ضد trem2 واستخداماته
HUE062436T2 (hu) 2017-08-03 2023-11-28 Alector Llc Anti-trem2 antitestek és alkalmazási módszereik
MX2020006213A (es) 2017-12-12 2020-09-14 Pionyr Immunotherapeutics Inc Anticuerpos anti-trem2 y metodos relacionados.
CA3109763A1 (en) * 2018-08-16 2020-02-20 Denali Therapeutics Inc. Engineered bispecific proteins
UY38407A (es) 2018-10-15 2020-05-29 Novartis Ag Anticuerpos estabilizadores de trem2
CA3120875A1 (en) 2018-12-11 2020-06-18 Pionyr Immunotherapeutics, Inc. Methods of using anti-trem2 antibodies
JP7543290B2 (ja) 2019-02-20 2024-09-02 デナリ セラピューティクス インコーポレイテッド 抗trem2抗体及びその使用方法
CN110511240B (zh) * 2019-08-27 2022-03-08 南京医科大学 一种髓细胞触发受体2的内源性配体及其应用
CN115003699A (zh) 2019-12-05 2022-09-02 艾利妥 抗trem2抗体的使用方法
US20230265212A1 (en) * 2019-12-19 2023-08-24 Kevin S. EISENFRATS Compositions and methods for oocyte-specific contraception
WO2021146256A1 (en) * 2020-01-13 2021-07-22 Denali Therapeutics Inc. Anti-trem2 antibodies and methods of use thereof
US11124567B2 (en) * 2020-01-13 2021-09-21 Denali Therapeutics Inc. Anti-TREM2 antibodies and methods of use thereof
CN115768794A (zh) 2020-02-24 2023-03-07 艾利妥 抗trem2抗体的使用方法
CA3172451A1 (en) 2020-04-03 2021-10-07 Robert Paul Methods of use of anti-trem2 antibodies
CN111793131A (zh) * 2020-05-11 2020-10-20 廊坊天光生物技术有限公司 一种用于检测血清中pf4含量的抗体对及其用途
CN116323667A (zh) * 2020-07-08 2023-06-23 拉法医疗股份有限公司 结合PSMA和γ-δT细胞受体的抗体
CN114075284B (zh) * 2020-08-17 2023-11-17 上海元宋生物技术有限公司 Cd47结合分子及其用途
WO2022045865A1 (ko) * 2020-08-31 2022-03-03 (주)메디톡스 항-vegf 육량체 항체, 및 이를 포함하는 조성물
US20240102094A1 (en) * 2020-12-03 2024-03-28 Amgen Inc. Trem2 agonist biomarkers and methods of use thereof
WO2022241082A1 (en) 2021-05-14 2022-11-17 Genentech, Inc. Agonists of trem2
IL308804A (en) * 2021-05-28 2024-01-01 Vigil Neuroscience Inc TREM2 agonistic biomarkers and methods of using them
CN115505041B (zh) * 2021-06-22 2026-05-05 北京免疫方舟医药科技有限公司 抗EphA2抗体及其应用
IL285416A (en) * 2021-08-05 2023-03-01 Yeda Res & Dev Antibodies for cancer treatment
IL311003A (en) 2021-08-25 2024-04-01 Denali Therapeutics Inc Anti-2HER antibodies and methods of using them
US20240392035A1 (en) * 2021-08-25 2024-11-28 Denali Therapeutics Inc. Engineered anti-her2 bispecific proteins
WO2023039612A1 (en) * 2021-09-13 2023-03-16 The Board Of Regents Of The University Of Texas System Trem2 antigen binding proteins and uses thereof
MX2024010324A (es) 2022-02-23 2024-08-30 Alector Llc Metodos de uso de anticuerpos anti-trem2.
EP4499695A1 (en) 2022-03-28 2025-02-05 Denali Therapeutics Inc. Methods for treating brain glucose hypometabolism
EP4499693A1 (en) 2022-03-28 2025-02-05 Denali Therapeutics Inc. Monovalent anti-trem2 binding molecules and methods of use thereof
WO2023215697A1 (en) * 2022-05-05 2023-11-09 Eli Lilly And Company Multispecific binding molecules and methods of use thereof
JP2025529287A (ja) 2022-09-06 2025-09-04 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル マルファン症候群の処置のためのtrem-2アゴニスト
US20240262929A1 (en) * 2023-02-06 2024-08-08 Ibio, Inc. Anti-muc16 antibodies
AU2024320793A1 (en) 2023-08-09 2026-03-12 F. Hoffmann-La Roche Ag Mono and multispecific anti-trem2 antibodies, methods and uses thereof
AU2024323186A1 (en) 2023-08-09 2026-01-15 F. Hoffmann-La Roche Ag Mono and multispecific anti-trem2 antibodies, methods and uses thereof
WO2025046298A2 (en) * 2023-09-01 2025-03-06 iTeos Belgium SA Anti-trem2 antibodies and methods of use

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104520329A (zh) * 2012-08-29 2015-04-15 霍夫曼-拉罗奇有限公司 血脑屏障穿梭体
CN107106679A (zh) * 2014-08-08 2017-08-29 艾利妥 抗trem2抗体及其使用方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002021141A2 (en) 2000-09-06 2002-03-14 Aventis Pharma S.A. Methods and compositions for diseases associated with amyloidosis
CN102268094A (zh) 2002-08-30 2011-12-07 比奥雷克西斯药物公司 被修饰的转铁蛋白抗体的融合蛋白
DK2046826T3 (da) 2006-07-24 2011-10-24 Biorexis Pharmaceutical Corp Exendin-fusionsproteiner
TWI507525B (zh) * 2009-06-26 2015-11-11 Regeneron Pharma 具天然免疫球蛋白形式之易分離的雙專一性抗體
WO2017058866A1 (en) * 2015-09-28 2017-04-06 Precision Immune, Inc. Anti-trem2 antibodies and uses thereof
JP7725185B2 (ja) 2015-10-06 2025-08-19 アレクトル エルエルシー 抗trem2抗体及びその使用方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104520329A (zh) * 2012-08-29 2015-04-15 霍夫曼-拉罗奇有限公司 血脑屏障穿梭体
CN107106679A (zh) * 2014-08-08 2017-08-29 艾利妥 抗trem2抗体及其使用方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
周宓等: "跨血脑屏障药物转运的研究进展" *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114667295A (zh) * 2019-11-22 2022-06-24 伊莱利利公司 Trem2抗体及其用途
CN114667295B (zh) * 2019-11-22 2024-03-29 伊莱利利公司 Trem2抗体及其用途
CN112526143A (zh) * 2020-12-03 2021-03-19 中山大学附属第五医院 髓系细胞触发受体2作为新型冠状病毒肺炎诊断或治疗靶点的应用
WO2024250809A1 (zh) * 2023-06-08 2024-12-12 成都优洛生物科技有限公司 抗trem2全人源抗体或其抗原结合片段及其应用
CN117534569A (zh) * 2023-11-23 2024-02-09 复旦大学附属华山医院 S-9-pahsa在制备阿尔兹海默病及认知障碍疾病治疗药物中的用途
CN117964768A (zh) * 2024-04-02 2024-05-03 上海宏成药业有限公司 抗trem2抗体及其用途

Also Published As

Publication number Publication date
JP2025133893A (ja) 2025-09-11
WO2019055841A1 (en) 2019-03-21
JP2020534277A (ja) 2020-11-26
JP7403441B2 (ja) 2023-12-22
EP3681909A1 (en) 2020-07-22
US20200277373A1 (en) 2020-09-03
CA3075285A1 (en) 2019-03-21
JP2023163183A (ja) 2023-11-09

Similar Documents

Publication Publication Date Title
JP7403441B2 (ja) 抗trem2抗体及びその使用方法
US11124567B2 (en) Anti-TREM2 antibodies and methods of use thereof
US11370832B2 (en) Anti-Tau antibodies and methods of use thereof
AU2021208482B2 (en) Anti-TREM2 antibodies and methods of use thereof
JP7159185B2 (ja) 抗phf-タウ抗体及びその使用
TWI879756B (zh) 抗trem2抗體及其使用方法
JP2020168003A (ja) 抗FcRn抗体
JP7362636B2 (ja) 抗phf-タウ抗体及びその使用
WO2018237338A1 (en) Anti-alpha-synuclein antibodies and methods of use thereof
CN112739422B (zh) Cd200r激动剂抗体及其用途
WO2019094576A1 (en) Bace-tau bispecific antibodies
KR20230034367A (ko) 항-종양 괴사 인자 수용체 (tnfr2) 항체 및 그 용도
KR20220092859A (ko) 항-cxcr2 항체 및 이의 용도
US20250215077A1 (en) Monovalent anti-trem2 binding molecules and methods of use thereof
HK40086025B (en) Anti-human nr1 antibody derivative

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination